<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332133</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetic Macular Edema(DME)</org_study_id>
    <nct_id>NCT04332133</nct_id>
  </id_info>
  <brief_title>Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema</brief_title>
  <official_title>Anatomical and Functional Outcomes of Subthreshold Micropulse Laser Versus Intravitreal Ranibizumab Injection in Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is To compare the anatomical and functional results of intravitreal(
      IV) injection of ranibizumab with sub threshold micropulse laser ( SML) in treatment of
      Diabetic macular edema (DME) both anatomically by spectral domain optical coherence
      tomography (SD OCT) and functionally by best-corrected visual acuity (BCVA) and multifocal
      electroretinogram (mfERG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular edema (DME) causes significant visual loss in diabetic patients. About 20%
      and 40% of patients with Type 1 and Type 2 diabetes mellitus (DM), respectively, develop DME.
      One-third of diabetic patients who have had DM for more than twenty years will develop DME .
      Early impairment in the function of the middle and inner layers of the retina has been
      reported in diabetic patients before appearance of vascular complications . A good
      independent guide of macular function in patients with DME is multifocal electroretinogram
      (mfERG) readings from the macular area, which strongly associate with morphologic alterations
      in the macula. Some investigators suggested that temporal characteristic (implicit time) of
      mfERG waves are more important than amplitudes for evaluation of retinal function in diabetic
      patients. They concluded that patients with DM show temporal changes indicating delayed
      neural transmission due to local impairment of blood glucose metabolism. In contrast, others
      emphasize the importance of both parameters (implicit time and amplitude) in identifying
      retinal affection in DM.

      Intravitreal (IV) injections of anti-vascular endothelial growth factor (VEGF) agents
      provided good visual outcomes in treatment of DME. However, IV anti-VEGF injections are
      expensive, need to be repeated many times and have the potential risk of causing
      endophthalmitis . Subthreshold micropulse laser (SML) treatment of DME has the same effect as
      conventional laser treatment, nonetheless, there is less damage to adjacent tissues of the
      burn area in the retinal pigment epithelium (RPE). SML allows laser emission to be divided
      into bursts of short cyclic pulses that remain for microseconds permitting substantial
      cooling amid these short pulses .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central subfield thickness in micrometer</measure>
    <time_frame>6 months</time_frame>
    <description>OCT for the macular area with measuring CST in micron</description>
  </primary_outcome>
  <primary_outcome>
    <measure>p1 amplitude of mfERG</measure>
    <time_frame>6mnths</time_frame>
    <description>p1 amplitude of multifocal ERG measured in nv/deg2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BCVA</measure>
    <time_frame>6 months</time_frame>
    <description>BCVA is measured in decimal of Snellen visual acuity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 1 of DME which treated by SML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 of DME which treated by intravitreal injection of Ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group of diabetic patients received no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laser interference,INTRAVITREAL INJECTION</intervention_name>
    <description>sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DME with BCVA&lt;0.5 decimal Snellen acuity.

          -  Controlled blood glucose (HbA1c) &lt;6.5%.

        Exclusion Criteria:

          -  History of previous intraocular surgery,

          -  History of previous laser treatment,

          -  History of previous IV injection,

          -  Macular disease or ischemia,

          -  Proliferative diabetic retinopathy,

          -  Vitreoretinal traction,

          -  Interruption of external limiting membrane (ELM) or ellipsoid zone (EZ).

          -  Dense media opacity,

          -  Optic disc pathology

          -  History of strokes or ischaemic heart diseases.

          -  patients with (CST) &gt; 400 Âµm on OCT .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raafat Abdallah, A.professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ophthalmology department,faculty of medicine, minia university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud Genidy, professor</last_name>
    <role>Study Director</role>
    <affiliation>ophthalmology department,faculty of medicine, minia university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wagiha Massoud, professor</last_name>
    <role>Study Chair</role>
    <affiliation>ophthalmology department,faculty of medicine, minia university</affiliation>
  </overall_official>
  <reference>
    <citation>Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009 Mar;116(3):497-503. doi: 10.1016/j.ophtha.2008.10.016. Epub 2009 Jan 22.</citation>
    <PMID>19167079</PMID>
  </reference>
  <reference>
    <citation>Lung JC, Swann PG, Wong DS, Chan HH. Global flash multifocal electroretinogram: early detection of local functional changes and its correlations with optical coherence tomography and visual field tests in diabetic eyes. Doc Ophthalmol. 2012 Oct;125(2):123-35. doi: 10.1007/s10633-012-9343-0. Epub 2012 Jul 25.</citation>
    <PMID>22828871</PMID>
  </reference>
  <reference>
    <citation>Yamamoto S, Yamamoto T, Hayashi M, Takeuchi S. Morphological and functional analyses of diabetic macular edema by optical coherence tomography and multifocal electroretinograms. Graefes Arch Clin Exp Ophthalmol. 2001 Feb;239(2):96-101.</citation>
    <PMID>11372551</PMID>
  </reference>
  <reference>
    <citation>Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2638-51.</citation>
    <PMID>10509661</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Raafat Mohyeldeen Abdelrahman Abdallah</investigator_full_name>
    <investigator_title>associate professor of ophthalmology</investigator_title>
  </responsible_party>
  <keyword>DME, mfERG, SML, ranibizumab,IV.injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results can be shred after the end of the work.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>after publication has been completed</ipd_time_frame>
    <ipd_access_criteria>personal communication through email or through this site if possible</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

